Neuropsychiatric symptoms profile and markers of Alzheimer disease–type pathology in patients with Lewy body dementias

•We propose that in LBD, there is a specific association between the pathophysiology of AD and NPS.•Specifically, depressive symptoms in LBD are linked to the burden of AD-type pathology.•Defining LBD based on shared pathological markers of AD may offer advantages over relying exclusively on clinica...

Full description

Saved in:
Bibliographic Details
Published in:Brain research 2024-06, Vol.1833, p.148881-148881, Article 148881
Main Authors: Geng, Chaofan, Tan, Leilei, Chen, Chen
Format: Article
Language:English
Subjects:
Amyloid beta 42
CSF
DLB
Neuropsychiatric symptoms
Phosphorylated tau
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•We propose that in LBD, there is a specific association between the pathophysiology of AD and NPS.•Specifically, depressive symptoms in LBD are linked to the burden of AD-type pathology.•Defining LBD based on shared pathological markers of AD may offer advantages over relying exclusively on clinically defined syndromes (DLB, PDD), as identifying AD-type and synuclein pathology. To determine whether Lewy body dementia (LBD) patients with likely copathology of Alzheimer’s disease (AD) exhibit greater neuropsychiatric symptom (NPS) compared to those without likely AD-type copathology. We enrolled 69 individuals diagnosed with Lewy body dementia (LBD), comprising both dementia with Lewy bodies (DLB) (n = 36) and Parkinson's disease dementia (PDD) (n = 33). These participants had accessible cerebrospinal fluid (CSF) markers related to Alzheimer's disease (AD) and cognitive data. We assessed CSF levels of β-amyloid 42 (Aβ42), phosphorylated tau (p-tau), and total tau (t-tau). Employing autopsy-validated CSF thresholds (t-tau/Aβ42 ratio > 0.3, n = 69), we categorized individuals into LBD with AD pathology (LBD + AD, n = 31) and LBD without apparent AD co-pathology (LBD - AD, n = 38). Moreover, the Hamilton Depression Scale (HAMD24), Hamilton Anxiety Scale (HAMA14), and Neuropsychiatric Inventory Questionnaire (NPI-Q) was used to assess the NPS. Spearman correlations were utilized to explore links between NPS and CSF marker profiles. In terms of neuropsychiatric symptoms, LBD + AD patients demonstrated notably elevated levels of depressive symptoms (HAMD24) in comparison to LBD - AD patients (P 
ISSN:0006-8993
1872-6240
DOI:10.1016/j.brainres.2024.148881